Dicerna | GenomeWeb

Dicerna

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

Dicerna's new RNAi triggers and conjugate technology are entirely proprietary and fall outside of intellectual property held by other organizations, according to a company official.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals last week reported its third-quarter financial results, posting higher losses amid increased spending on its drug-development programs.
Dicerna's net loss for the period rose to $11.2 million from $4.5 million the year before.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track to enter new clinical trials later this year and in 2

Key RNAi Drugs in the Clinic

Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week announced preclinical data showing that its investigational primary hyperoxaluria type 1 (PH1) therapy DCR-PH1 could silence expression of its target by as much as 97 percent in a mouse model of the disease.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week reported its first-quarter financial results, posting a jump in its net loss due to higher costs associated with drug development and its recently completed initial public offering.

NEW YORK (GenomeWeb) – Amid a recent downturn among biotechnology stocks, shares of the top eight publicly traded RNAi and microRNA drug developers have fared particularly poorly, shedding an average of 37 percent of their value from their year-to-date highs.

Dicerna Pharmaceuticals this week announced that it has begun dosing patients in a Phase I trial of its RNAi cancer treatment DCR-MYC, formerly known as DCR-M1711.

Officials from newly public Dicerna Pharmaceuticals last week provided an update on the company's two pipeline programs, offering some details on the planned Phase I program for its lead cancer therapeutic, as well as timing on when a new drug candidate will be named.

Pages

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.